SCI Abstract

search
Light on nonmotor symptoms in Parkinson’s disease patients: The impact on quality of life
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Mitochondrial rescue in Alzheimer’s disease: Exploring marine-derived compounds for brain metabolism regulation
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Glial molecular signatures as a liquid biopsy marker in Alzheimer’s disease diagnosis
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
TMEM230 and mitochondrial regulation in Alzheimer’s disease
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Redox bioenergetics of neuronal senescence in Alzheimer’s disease
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Circadian rhythm, metabolic stress, and Alzheimer’s disease
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Redefining Alzheimer’s disease diagnostics in the age of blood-based biomarkers
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Metabolic dysregulation in Alzheimer’s disease: Mechanisms, markers, and therapeutic prospects
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
The clinical utility of blood-based biomarkers of Alzheimer’s disease: Triumphs and pitfalls
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Metabolic therapeutic targets in Alzheimer’s disease
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Astroglial dysregulation and gliotransmitter imbalance in schizophrenia
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Intestinal microbiota in neurodegeneration and ageing: Mechanisms, pathways, and therapeutic interventions
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Energetic crisis, mitochondrial vulnerability and disruption of lactate shuttle in Alzheimer’s disease
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
From metals to mitochondria: Linking trace elements to energy crisis in Alzheimer’s disease
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
The microbiota-gut–brain axis in epilepsy: Mechanistic insights and emerging probiotic-based therapeutics
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Neurovascular coupling and energy substrate delivery in Alzheimer’s disease
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Chaper One - Typical and atypical clinical presentations
Autoimmune myasthenia gravis (MG) is caused by autoantibodies targeting the neuromuscular junction at the postsynaptic lev...
Chapter Two - Diagnosis of MG and differential diagnoses
The diagnostic workup for myasthenia gravis extends beyond the objective evaluation of skeletal muscle fatigue during neur...
Chapter Three - The clinical evaluation of myasthenia gravis
The most important clue to myasthenia as a possible diagnosis, is the description of muscle fatigability uncovered during ...
Chapter Four - Myasthenia gravis in women
Transient neonatal MG is caused by the transplacental transfer of IgG antibodies from the mother to the fetus, starting in...
Chapter Five - Clinical outcome measures
The World Health Organization defines health as a state of complete physical, mental, and social well-being and not merely...
Chapter Six - Traditional treatments and different geographical approaches
Treatment and clinical research in myasthenia gravis (MG) have had major advances during the past 60 years. The 1930s saw ...
Chapter Seven - Rescue therapy in myasthenia gravis
Myasthenia gravis (MG) is a complex autoimmune neuromuscular disorder marked by fluctuating weakness in voluntary muscles....
Chapter Eight - Novel treatments for myasthenia gravis
Advances in immunology over the last several years have provided insights into the pathophysiology of autoimmune diseases ...
Chapter Nine - Measuring treatment related side effect burden in myasthenia gravis
Myasthenia gravis (MG) treatments are rapidly increasing. Since 2021, the FDA approved 6 new MG therapies including IV and...
Chapter Ten - Exercise and myasthenia gravis
Despite the limited number of studies, evidence consistently supports the safety and benefits of exercise for individuals ...